Qelbree

Chemical Nameviloxazine
Dosage FormExtended-release capsule (oral; 100 mg, 150 mg and 200 mg)
Drug ClassInhibitors
SystemNervous
CompanySupernus Pharmaceuticals, Inc.
Approval Year2021

Indication

  • Indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
Last updated on 4/13/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Qelbree (viloxazine) Prescribing Information2021Supernus Pharmaceuticals, Inc. Rockville, MD